Palisade Bio公布补充1a/B期数据 证实结肠靶向暴露与持续Ic90覆盖 支持溃疡性结肠炎每日一次给药方案

美股速递
May 05

生物制药公司Palisade Bio Inc.最新发布的1a/B期临床试验补充数据显示,其候选药物在溃疡性结肠炎治疗中展现出显著的结肠靶向暴露特性。数据证实药物能够精准递送至病变部位,并维持超过90%抑制浓度(Ic90)的有效覆盖,这一突破性发现为每日单次给药方案提供了强有力支持。

研究结果表明,该结肠靶向技术可确保药物在肠道特定区域释放,最大限度提升局部疗效同时降低全身性副作用风险。持续达到的Ic90覆盖水平证明药物能在24小时内保持治疗浓度,颠覆了传统多次给药模式,有望显著改善患者用药依从性与生活质量。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10